Novo Nordisk vs. Amgen: Weight Loss Drug Competition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy NVO?
Source: NASDAQ.COM
- Market Leadership: Novo Nordisk leads the weight loss market with its GLP-1 drug Wegovy, and the recent launch of its oral version further solidifies its market share, with expectations to expand its portfolio of weight loss medicines in the coming years, driving company growth.
- R&D Progress: Novo Nordisk's CagriSema outperformed Wegovy in clinical studies and is under consideration for approval, while candidates like amycretin and UBT251 are also in active development, showcasing the company's strong R&D capabilities in the weight loss sector.
- Amgen's Potential: Although Amgen has yet to launch a weight loss drug, its candidate MariTide is in phase 3 studies and could gain approval within the next three years, with its monthly dosing regimen potentially providing a competitive edge.
- Investment Risk Assessment: Novo Nordisk's growth is heavily reliant on the performance of its weight loss drugs, while Amgen offers a more diversified product portfolio, suggesting that even if its weight loss market performance is uncertain, its overall business resilience may provide investors with lower risk.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 39.780
Low
42.00
Averages
54.67
High
70.00
Current: 39.780
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Opportunities in Healthcare Stocks
- Pfizer's Stock Appeal: Pfizer is currently trading at a P/E ratio of 9, significantly lower than the healthcare sector's average of 18.5, making it an attractive option for long-term investors looking to buy before a potential rebound, especially given its robust pipeline.
- Clinical Trial Progress: The company plans to initiate over a dozen phase 3 clinical trials this year, and even with a modest 50% success rate, it is expected to launch several new products that could drive revenue growth and enhance market competitiveness.
- Novo Nordisk's Market Outlook: Trading at 10.5 times forward earnings, Novo Nordisk faces competition from Eli Lilly but has promising candidates like CagriSema that outperform Wegovy, positioning it well in the rapidly growing weight loss market.
- Innovative Drug Development: Novo Nordisk's UBT251 showed excellent results in mid-stage studies in China, potentially becoming the first approved product in the anti-obesity space, and with Wegovy's new label expansions, it could significantly increase market share.
See More
Pfizer and Novo Nordisk Stock Attractiveness Analysis
- Pfizer Stock Valuation: Pfizer is currently trading at a forward P/E ratio of 9, significantly lower than the healthcare sector average of 18.5, indicating its stock is attractive given its robust pipeline that is expected to enhance financial performance.
- Clinical Trial Progress: The company plans to initiate over a dozen phase 3 clinical trials this year, and even with a modest 50% success rate, it is poised to launch several new products, particularly in oncology and weight loss, driving future revenue growth.
- Novo Nordisk Market Competition: Novo Nordisk has lost its leading position in the weight loss market to Eli Lilly, with sales expected to decline in 2026; however, its stock is currently trading at a forward P/E of 10.5, suggesting investment potential.
- New Product Potential: Novo Nordisk's next-gen candidate CagriSema has proven more effective than Wegovy, and its UBT251 showed excellent results in a mid-stage study in China, potentially bringing new growth opportunities in the anti-obesity space.
See More
Novo Nordisk Receives Warning Letter from FDA
- FDA Warning Letter: The US FDA has issued a warning letter to Novo Nordisk, accusing the company of failing to comply with postmarketing adverse event reporting requirements, indicating significant compliance deficiencies that could impact its market reputation and future product approvals.
- Investigation Period: The FDA conducted an investigation from January to February 2025, and despite Novo's multiple written responses, the agency noted that the company did not adhere to applicable statutory requirements and regulations, highlighting serious shortcomings in compliance management.
- Product Impact: With semaglutide as the active ingredient in Wegovy and Ozempic, and liraglutide in Victoza and Saxenda, the FDA's warning could negatively affect the market performance and sales of these products, thereby impacting the company's overall financial performance.
- Compliance Requirements: The FDA mandates that Novo Nordisk develop written procedures to ensure compliance with all applicable regulations for the surveillance, receipt, evaluation, and reporting of postmarketing adverse events, and failure to meet these requirements could lead to further regulatory actions and financial penalties.
See More
European Natural Gas Prices Hit Three-Year High Amid Geopolitical Tensions
- Price Surge: European natural gas prices soared to a three-year high on Tuesday due to ongoing US-Israeli military operations against Iran, with the Dutch TTF rising 68% for the week ending March 6, indicating potential long-term disruptions to LNG supplies.
- Inventory Decline: The Energy Information Administration reported a draw of 132 bcf in natural gas inventories for the week ending February 27, exceeding market expectations of 124 bcf, highlighting increasing supply tightness that could lead to further price hikes.
- Market Reaction: West Texas Intermediate crude surged nearly 30% to $120 a barrel on Sunday night before dropping 15% to near $100, reflecting the market's heightened sensitivity to Middle Eastern energy supply concerns, which may destabilize global energy markets.
- Economic Outlook: Although the economic impact of the Iran conflict has yet to materialize, weak industrial production data from the Euro Area and the UK indicates fragile growth, with traders anticipating two rate cuts from the European Central Bank this year, reflecting concerns about future economic conditions.
See More
BofA Nearly Doubles HIMS Price Target to $23 Following Novo Deal
- Price Target Surge: BofA has nearly doubled its price target for HIMS from $12.5 to $23, upgrading its rating from ‘Underperform’ to ‘Neutral’, indicating a significant boost in market confidence towards the company.
- Litigation Risk Mitigated: The dropping of the patent infringement lawsuit by Novo Nordisk is viewed as a “clear positive” for the telehealth operator, alleviating legal burdens and creating a more favorable environment for HIMS's future growth.
- Positive Market Reaction: Following the announcement, HIMS shares rose nearly 5%, while Novo shares dipped 1%, reflecting strong investor optimism for HIMS, with retail sentiment trending towards ‘extremely bullish’ territory.
- Partnership Agreement Details: HIMS and Novo have partnered to offer Ozempic and Wegovy at self-pay prices on HIMS's platform, discontinuing the advertisement of compounded GLP-1 products, a strategic shift expected to enhance HIMS's market competitiveness.
See More
Market Update: Oil Price Drop and Tech Stock Upgrades
- Oil Price Fluctuations: U.S. benchmark WTI crude prices have fallen below $90 a barrel, despite being up over 50% year-to-date, indicating market optimism regarding improved U.S.-Iran relations, yet geopolitical risks continue to loom over oil prices.
- Tech Stock Rating Changes: Intuit was upgraded to buy from hold by Rothschild & Co Redburn, with its stock rising over 30% since late February, although it remains down 28.5% for the year, reflecting a recovery in market confidence in its software products.
- Cybersecurity Stock Bounce: Morgan Stanley upgraded CrowdStrike from hold to buy, with its stock up over 20% from last month's low, highlighting the positive impact of AI technology on the cybersecurity sector and indicating optimistic market expectations for future growth.
- Hewlett Packard Enterprise's Positive Outlook: Despite memory cost pressures, the company raised its full-year earnings outlook, with reported quarterly revenues slightly below expectations but gross margins and adjusted EPS exceeding forecasts, demonstrating strong demand in the data center buildout.
See More
Investment Opportunities in Healthcare Stocks
- Pfizer's Stock Appeal: Pfizer is currently trading at a P/E ratio of 9, significantly lower than the healthcare sector's average of 18.5, making it an attractive option for long-term investors looking to buy before a potential rebound, especially given its robust pipeline.
- Clinical Trial Progress: The company plans to initiate over a dozen phase 3 clinical trials this year, and even with a modest 50% success rate, it is expected to launch several new products that could drive revenue growth and enhance market competitiveness.
- Novo Nordisk's Market Outlook: Trading at 10.5 times forward earnings, Novo Nordisk faces competition from Eli Lilly but has promising candidates like CagriSema that outperform Wegovy, positioning it well in the rapidly growing weight loss market.
- Innovative Drug Development: Novo Nordisk's UBT251 showed excellent results in mid-stage studies in China, potentially becoming the first approved product in the anti-obesity space, and with Wegovy's new label expansions, it could significantly increase market share.
See More
Pfizer and Novo Nordisk Stock Attractiveness Analysis
- Pfizer Stock Valuation: Pfizer is currently trading at a forward P/E ratio of 9, significantly lower than the healthcare sector average of 18.5, indicating its stock is attractive given its robust pipeline that is expected to enhance financial performance.
- Clinical Trial Progress: The company plans to initiate over a dozen phase 3 clinical trials this year, and even with a modest 50% success rate, it is poised to launch several new products, particularly in oncology and weight loss, driving future revenue growth.
- Novo Nordisk Market Competition: Novo Nordisk has lost its leading position in the weight loss market to Eli Lilly, with sales expected to decline in 2026; however, its stock is currently trading at a forward P/E of 10.5, suggesting investment potential.
- New Product Potential: Novo Nordisk's next-gen candidate CagriSema has proven more effective than Wegovy, and its UBT251 showed excellent results in a mid-stage study in China, potentially bringing new growth opportunities in the anti-obesity space.
See More
Novo Nordisk Receives Warning Letter from FDA
- FDA Warning Letter: The US FDA has issued a warning letter to Novo Nordisk, accusing the company of failing to comply with postmarketing adverse event reporting requirements, indicating significant compliance deficiencies that could impact its market reputation and future product approvals.
- Investigation Period: The FDA conducted an investigation from January to February 2025, and despite Novo's multiple written responses, the agency noted that the company did not adhere to applicable statutory requirements and regulations, highlighting serious shortcomings in compliance management.
- Product Impact: With semaglutide as the active ingredient in Wegovy and Ozempic, and liraglutide in Victoza and Saxenda, the FDA's warning could negatively affect the market performance and sales of these products, thereby impacting the company's overall financial performance.
- Compliance Requirements: The FDA mandates that Novo Nordisk develop written procedures to ensure compliance with all applicable regulations for the surveillance, receipt, evaluation, and reporting of postmarketing adverse events, and failure to meet these requirements could lead to further regulatory actions and financial penalties.
See More
European Natural Gas Prices Hit Three-Year High Amid Geopolitical Tensions
- Price Surge: European natural gas prices soared to a three-year high on Tuesday due to ongoing US-Israeli military operations against Iran, with the Dutch TTF rising 68% for the week ending March 6, indicating potential long-term disruptions to LNG supplies.
- Inventory Decline: The Energy Information Administration reported a draw of 132 bcf in natural gas inventories for the week ending February 27, exceeding market expectations of 124 bcf, highlighting increasing supply tightness that could lead to further price hikes.
- Market Reaction: West Texas Intermediate crude surged nearly 30% to $120 a barrel on Sunday night before dropping 15% to near $100, reflecting the market's heightened sensitivity to Middle Eastern energy supply concerns, which may destabilize global energy markets.
- Economic Outlook: Although the economic impact of the Iran conflict has yet to materialize, weak industrial production data from the Euro Area and the UK indicates fragile growth, with traders anticipating two rate cuts from the European Central Bank this year, reflecting concerns about future economic conditions.
See More
BofA Nearly Doubles HIMS Price Target to $23 Following Novo Deal
- Price Target Surge: BofA has nearly doubled its price target for HIMS from $12.5 to $23, upgrading its rating from ‘Underperform’ to ‘Neutral’, indicating a significant boost in market confidence towards the company.
- Litigation Risk Mitigated: The dropping of the patent infringement lawsuit by Novo Nordisk is viewed as a “clear positive” for the telehealth operator, alleviating legal burdens and creating a more favorable environment for HIMS's future growth.
- Positive Market Reaction: Following the announcement, HIMS shares rose nearly 5%, while Novo shares dipped 1%, reflecting strong investor optimism for HIMS, with retail sentiment trending towards ‘extremely bullish’ territory.
- Partnership Agreement Details: HIMS and Novo have partnered to offer Ozempic and Wegovy at self-pay prices on HIMS's platform, discontinuing the advertisement of compounded GLP-1 products, a strategic shift expected to enhance HIMS's market competitiveness.
See More
Market Update: Oil Price Drop and Tech Stock Upgrades
- Oil Price Fluctuations: U.S. benchmark WTI crude prices have fallen below $90 a barrel, despite being up over 50% year-to-date, indicating market optimism regarding improved U.S.-Iran relations, yet geopolitical risks continue to loom over oil prices.
- Tech Stock Rating Changes: Intuit was upgraded to buy from hold by Rothschild & Co Redburn, with its stock rising over 30% since late February, although it remains down 28.5% for the year, reflecting a recovery in market confidence in its software products.
- Cybersecurity Stock Bounce: Morgan Stanley upgraded CrowdStrike from hold to buy, with its stock up over 20% from last month's low, highlighting the positive impact of AI technology on the cybersecurity sector and indicating optimistic market expectations for future growth.
- Hewlett Packard Enterprise's Positive Outlook: Despite memory cost pressures, the company raised its full-year earnings outlook, with reported quarterly revenues slightly below expectations but gross margins and adjusted EPS exceeding forecasts, demonstrating strong demand in the data center buildout.
See More
